SG11201605653RA - Pharmaceutical preparation containing pyridylaminoacetic acid compound - Google Patents

Pharmaceutical preparation containing pyridylaminoacetic acid compound

Info

Publication number
SG11201605653RA
SG11201605653RA SG11201605653RA SG11201605653RA SG11201605653RA SG 11201605653R A SG11201605653R A SG 11201605653RA SG 11201605653R A SG11201605653R A SG 11201605653RA SG 11201605653R A SG11201605653R A SG 11201605653RA SG 11201605653R A SG11201605653R A SG 11201605653RA
Authority
SG
Singapore
Prior art keywords
acid compound
pharmaceutical preparation
preparation containing
pyridylaminoacetic acid
containing pyridylaminoacetic
Prior art date
Application number
SG11201605653RA
Other languages
English (en)
Inventor
Naveed Shams
Henk-Andre Kroon
Hisashi KAWATA
Noriko Kawabata
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201605653R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of SG11201605653RA publication Critical patent/SG11201605653RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201605653RA 2014-01-10 2015-01-08 Pharmaceutical preparation containing pyridylaminoacetic acid compound SG11201605653RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925882P 2014-01-10 2014-01-10
PCT/JP2015/050366 WO2015105144A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物を含む医薬製剤

Publications (1)

Publication Number Publication Date
SG11201605653RA true SG11201605653RA (en) 2016-08-30

Family

ID=53520400

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605653RA SG11201605653RA (en) 2014-01-10 2015-01-08 Pharmaceutical preparation containing pyridylaminoacetic acid compound

Country Status (26)

Country Link
US (8) US9415038B2 (de)
EP (3) EP3750541A1 (de)
JP (6) JP5846338B2 (de)
KR (1) KR101824829B1 (de)
CN (2) CN108743587B (de)
AU (1) AU2015205188B2 (de)
BR (1) BR112016015763B8 (de)
CA (1) CA2936026C (de)
CL (1) CL2016001756A1 (de)
DK (1) DK3093018T3 (de)
EA (1) EA031734B1 (de)
ES (2) ES2711091T3 (de)
GE (1) GEP20186917B (de)
HK (1) HK1223036A1 (de)
HU (1) HUE041653T2 (de)
IL (1) IL246447B (de)
MX (1) MX370361B (de)
MY (1) MY163235A (de)
PH (1) PH12016501357A1 (de)
PL (1) PL3093018T3 (de)
PT (1) PT3093018T (de)
SG (1) SG11201605653RA (de)
TR (1) TR201902019T4 (de)
TW (1) TWI598113B (de)
UA (1) UA117506C2 (de)
WO (1) WO2015105144A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015105144A1 (ja) * 2014-01-10 2015-07-16 参天製薬株式会社 ピリジルアミノ酢酸化合物を含む医薬製剤
BR112016015909B1 (pt) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético
EP3093021B1 (de) * 2014-01-10 2021-06-02 Santen Pharmaceutical Co., Ltd. Pyridylaminoessigsäureverbindungs- und polyoxyethylen-rizinusölhaltige pharmazeutische zusammensetzung
WO2016093346A1 (ja) * 2014-12-12 2016-06-16 興和株式会社 水性組成物
JP6872322B2 (ja) * 2015-07-01 2021-05-19 参天製薬株式会社 クエン酸エステルを含有するデポ剤
TWI794140B (zh) * 2015-07-09 2023-03-01 日商參天製藥股份有限公司 含有吡啶基胺基乙酸化合物之預防及/或治療劑
US11433090B2 (en) 2017-06-16 2022-09-06 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
EP3639855A4 (de) 2017-06-16 2021-03-17 The Doshisha Verbindungen mit caspasehemmender wirkung, pharmazeutisches mittel mit diesen verbindungen zur behandlung oder prävention von hornhautendothelsymptomen, -störungen oder -erkrankungen und anwendung dieses pharmazeutischen mittels
EP3689349A4 (de) * 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. Arzneimittel mit pyridylaminoessigsäureverbindung
EP3730143A4 (de) 2017-12-21 2021-08-18 Santen Pharmaceutical Co., Ltd. Omidenepag-kombination
EP3733179A4 (de) * 2017-12-28 2021-09-15 Santen Pharmaceutical Co., Ltd. Pharmazeutische zubereitung mit einer pyridylaminoessigsäureverbindung
US10610518B2 (en) * 2018-04-24 2020-04-07 Allergan, Inc. Presbyopia treatments

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
WO2009113600A1 (ja) 2008-03-12 2009-09-17 宇部興産株式会社 ピリジルアミノ酢酸化合物
DK2415763T3 (en) * 2009-03-30 2016-03-07 Ube Industries A pharmaceutical composition for the treatment or prevention of glaucoma
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
CA3099517C (en) * 2012-07-13 2022-04-26 Santen Pharmaceutical Co., Ltd. Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
WO2015105144A1 (ja) 2014-01-10 2015-07-16 参天製薬株式会社 ピリジルアミノ酢酸化合物を含む医薬製剤
BR112016015909B1 (pt) 2014-01-10 2020-09-29 Santen Pharmaceutical Co., Ltd. Composição farmacêutica contendo composto de ácido piridilaminoacético
EP3093021B1 (de) 2014-01-10 2021-06-02 Santen Pharmaceutical Co., Ltd. Pyridylaminoessigsäureverbindungs- und polyoxyethylen-rizinusölhaltige pharmazeutische zusammensetzung

Also Published As

Publication number Publication date
KR101824829B1 (ko) 2018-02-01
PH12016501357B1 (en) 2016-08-15
KR20160101030A (ko) 2016-08-24
PH12016501357A1 (en) 2016-08-15
US11197849B2 (en) 2021-12-14
US10179127B2 (en) 2019-01-15
CL2016001756A1 (es) 2017-05-12
EP3424503A1 (de) 2019-01-09
EP3750541A1 (de) 2020-12-16
CN105899209B (zh) 2018-09-11
USRE48183E1 (en) 2020-09-01
JP7087040B2 (ja) 2022-06-20
CA2936026A1 (en) 2015-07-16
AU2015205188A1 (en) 2016-07-14
TWI598113B (zh) 2017-09-11
IL246447B (en) 2020-06-30
JP2016027060A (ja) 2016-02-18
US20160324838A1 (en) 2016-11-10
CN108743587A (zh) 2018-11-06
BR112016015763B1 (pt) 2020-09-01
JPWO2015105144A1 (ja) 2017-03-23
EP3093018B1 (de) 2018-11-28
JP2021006593A (ja) 2021-01-21
JP2022111280A (ja) 2022-07-29
JP7402922B2 (ja) 2023-12-21
IL246447A0 (en) 2016-08-31
CN108743587B (zh) 2021-04-30
JP6785330B2 (ja) 2020-11-18
AU2015205188B2 (en) 2019-11-14
US20150196541A1 (en) 2015-07-16
US9943510B2 (en) 2018-04-17
PL3093018T3 (pl) 2019-05-31
NZ721620A (en) 2021-08-27
WO2015105144A1 (ja) 2015-07-16
MY163235A (en) 2017-08-30
GEP20186917B (en) 2018-11-12
DK3093018T3 (en) 2019-02-04
MX2016009063A (es) 2016-09-28
EA031734B1 (ru) 2019-02-28
BR112016015763B8 (pt) 2020-09-15
US20190105310A1 (en) 2019-04-11
US9415038B2 (en) 2016-08-16
JP6491588B2 (ja) 2019-03-27
CA2936026C (en) 2022-04-19
US20180169079A1 (en) 2018-06-21
EP3093018A4 (de) 2017-09-13
JP2024019479A (ja) 2024-02-09
CN105899209A (zh) 2016-08-24
TW201609186A (zh) 2016-03-16
HK1223036A1 (zh) 2017-07-21
JP2019108363A (ja) 2019-07-04
ES2711091T3 (es) 2019-04-30
US10702511B2 (en) 2020-07-07
PT3093018T (pt) 2019-01-10
US20220054466A1 (en) 2022-02-24
HUE041653T2 (hu) 2019-05-28
US11793798B2 (en) 2023-10-24
UA117506C2 (uk) 2018-08-10
ES2834334T3 (es) 2021-06-17
JP5846338B2 (ja) 2016-01-20
US20200289483A1 (en) 2020-09-17
MX370361B (es) 2019-12-10
EA201691402A1 (ru) 2016-10-31
EP3424503B1 (de) 2020-09-02
US20240000763A1 (en) 2024-01-04
TR201902019T4 (tr) 2019-03-21
EP3093018A1 (de) 2016-11-16

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
GB201419579D0 (en) Pharmaceutical compound
GB201511790D0 (en) Pharmaceutical compound
GB201414730D0 (en) Pharmaceutical compound
IL246447A0 (en) A pharmaceutical preparation containing a pyridylaminoacetic acid compound
GB201404922D0 (en) Pharmaceutical compounds
IL246655A0 (en) A medical preparation containing a pyridyl amino acetic acid compound
SG11201702298VA (en) Pharmaceutical preparation
GB201516411D0 (en) Pharmaceutical compound
GB201416513D0 (en) Pharmaceutical compounds
GB201417707D0 (en) Pharmaceutical compounds
SG11201708818VA (en) Pharmaceutical compound
PL3288966T3 (pl) Związek farmaceutyczny
GB201419570D0 (en) Pharmaceutical compound
GB201508022D0 (en) Pharmaceutical compounds
GB201507883D0 (en) Pharmaceutical compound
GB201411215D0 (en) Pharmaceutical compound
GB201502156D0 (en) Pharmaceutical compound
GB201406154D0 (en) Pharmaceutical compound
GB201402341D0 (en) Pharmaceutical compound
GB201416969D0 (en) Pharmaceutical compounds
GB201416968D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds
GB201416622D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds